Clinical Trials Directory

Trials / Completed

CompletedNCT01145469

Biomarkers in DNA Samples From Patients With Chronic Lymphocytic Leukemia Previously Treated With Fludarabine-Based Therapy

Genome Wide Association Study Evaluating Genetic Factors Related to the Efficacy and Tolerability of Fludarabine Treatment in Patients With CLL

Status
Completed
Phase
Study type
Observational
Enrollment
225 (actual)
Sponsor
Eastern Cooperative Oncology Group · Network
Sex
All
Age
18 Years – 120 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Studying samples of DNA in the laboratory from patients who received fludarabine-based treatment may help doctors learn more about the effects of fludarabine on cells. It may also help doctors understand how well patients respond to treatment. PURPOSE: This research study is studying DNA samples from patients with chronic lymphocytic leukemia previously treated with fludarabine-based therapy.

Detailed description

OBJECTIVES: * To identify genetic characteristics associated with the efficacy and toxicity of fludarabine-based treatment in patients with chronic lymphocytic leukemia who participated on E2997. * To validate these genetic characteristics with a cancer cell model system to confirm association and dissect the mechanism of effect. OUTLINE: Archived DNA samples are analyzed for genetic characteristics associated with the efficacy and toxicity to fludarabine-based treatment using Affymetrix 6.0 single nucleotide polymorphism arrays. The results are then compared with data of genes identified in a cancer cell model system, and with clinical data (response, toxicity, overall survival, and progression-free survival) associated with each patient sample.

Conditions

Interventions

TypeNameDescription
GENETICDNA analysis
GENETICgene expression analysis
GENETICpolymorphism analysis
OTHERlaboratory biomarker analysis
OTHERmedical chart review

Timeline

Start date
2010-06-01
Primary completion
2010-08-01
Completion
2010-08-01
First posted
2010-06-16
Last updated
2017-05-17

Source: ClinicalTrials.gov record NCT01145469. Inclusion in this directory is not an endorsement.